This trial aims to investigate the impact of two target levels uric acid-lowering therapy (ULT) caused by hyperuricemia (HU) on kidney function and CKD progression \[1\] measured by eGFR and albuminuria (A) \[2\]. The main current tasks include 1) estimation serum uric acid (SUA) level most potential preserving of kidney function 2) the new onset of gouts depending on SUA level, both in gouts' and CKD' objects 3) safety and side effects of target and ultralow SUA levels for evidence-based ULT optimal regime in CKD and non CKD with gout patients. 4) investigation of cardio vascular rick ratio depending on SUA level. The tasks also include 1. to determine U-curve or directly proportional relationship between SUA and eGFR-EPI in CKD 1-4 2. to evaluate the new onset of goat which depends on SUA level and renal function In this study the optimal ULT for kidney function based on target SUA level in 30 months' treatment with either allopurinol or febuxostat will be determined.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Clinical reduction of new onset of acute gout attacks
Timeframe: 30 months
Estimating CKD prognosis by eGFR
Timeframe: 30 months
Estimating CKD prognosis by Albuminuria
Timeframe: 30 months